Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR®: Biodistribution, pharmacokinetic features and in vivo antitumor activity

Journal of Controlled Release

Volumn 144, Issue 2, 2010, Pages 144-150

  Paolino, Donatella ^a   Cosco, Donato ^a   Racanicchi, Leda ^b   Trapasso, Elena ^c   Celia, Christian ^a   Iannone, Michelangelo ^d   Puxeddu, Efisio ^b   Costante, Giuseppe ^a   Filetti, Sebastiano ^e   Russo, Diego ^a   Fresta, Massimo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d ARPA Calabria Environmental Epidemiology Centre   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ARO cell xenograft model; Biodistribution; Gemcitabine; Pharmacokinetic; Unilamellar PEGylated liposomes

Indexed keywords

ARO CELL XENOGRAFT MODEL; BIODISTRIBUTIONS; GEMCITABINE; PEGYLATED LIPOSOMES; UNILAMELLAR;

BIOLOGICAL MATERIALS; CARRIER CONCENTRATION; DRUG DOSAGE; ENZYME INHIBITION; GLYCOLS; LIPOSOMES; PHARMACOKINETICS; PHOSPHOLIPIDS; TUMORS;

DRUG PRODUCTS;

DRUG CARRIER; GEMCITABINE; PEGYLATED UNILAMELLAR LIPOSOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; HEART; IN VIVO STUDY; LIVER PARENCHYMA; LUNG PARENCHYMA; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SPLEEN; THYROID CARCINOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DEOXYCYTIDINE; FLOXURIDINE; HALF-LIFE; LIPOSOMES; MICE; MICE, INBRED NOD; MICE, SCID; POLYETHYLENE GLYCOLS; RALOXIFENE; TISSUE DISTRIBUTION; UNILAMELLAR LIPOSOMES;

EID: 77952670492     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.02.021     Document Type: Article

References (37)

1. Cavallaro G., Maniscalco L., Licciardi M., Giammona G. Tamoxifen-loaded polymeric micelles: preparation, physico-chemical characterization and in vitro evaluation studies. Macromol. Biosci. 2004, 4:1028-1038.
2. Gabizon A.A., Shmeeda H., Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 2006, 16:175-183.
3. Toschi L., Finocchiaro G., Bartolini S., Gioia V., Cappuzzo F. Role of gemcitabine in cancer therapy. Future Oncol. 2005, 1:7-17.
4. Fossella F.V., Lippman S.M., Shin D.M., Tarassoff P., Calayag-Jung M., Perez-Soler R., Lee J.S., Murphy W.K., Glisson B., Rivera E., Hong W.K. Maximum-tolerated dose defined for single-agent gemcitabine. A phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 1997, 15:310-316.
5. Dasanu C.A. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin. Drug Saf. 2008, 7:703-716.
6. Abbruzzese J.L., Grunewald R., Weeks E.A., Gravel D., Adams T., Nowak B., Mineishi S., Tarassoff P., Satterlee W., Raberet M.N. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol. 1991, 9:491-498.
7. Storniolo A.M., Allerheiligen S.R.B., Pearce H.L. Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin. Oncol. 1997, 24(2 suppl 7):S7-2-S7-7.
8. Reddy L.H., Couvreur P. Novel approaches to deliver gemcitabine to cancers. Curr. Pharm. Des. 2008, 14:1124-1137.
9. Celano M., Calvagno M.G., Bulotta S., Paolino D., Arturi F., Rotiroti D., Filetti S., Fresta M., Russo D. Cytotoxic effects of Gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer 2004, 4:63.
10. Calvagno M.G., Celia C., Paolino D., Cosco D., Iannone M., Castelli F., Doldo P., Fresta M. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes. Curr. Drug Deliv. 2007, 4:89-101.
11. Immordino M.L., Brusa P., Rocco F., Arpicco S., Ceruti M., Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J. Control. Release 2004, 100:331-346.
12. Stella B., Arpicco S., Rocco F., Marsaud V., Renoir J.M., Cattel L., Couvreur P. Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int. J. Pharm. 2007, 344:71-77.
13. Paolino D., Cosco D., Licciardi M., Giammona G., Fresta M., Cavallaro G. polyaspartylhydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer drugs. Biomacromolecules 2008, 9:1117-1130.
14. Couvreur P., Stella B., Reddy L.H., Hillaireau H., Dubernet C., Desmae1le D., Lepetre-Mouelhi S., Rocco F., Dereuddre-Bosquet N., Clayette P., Rosilio V., Marsaud V., Renoir J.M., Cattel L. Squalenoyl nanomedicines as potential therapeutics. Nano Letters 2006, 6:2544-2548.
15. Reddy L.H., Dubernet C., Mouelhi S.L., Marque P.E., Desmaele D., Couvreur P. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J. Control. Release 2007, 124:20-27.
16. Pasut G., Canal F., Dalla Via L., Arpicco S., Veronese F.M., Schiavon O. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J. Control. Release 2008, 127:239-248.
17. Celia C., Calvagno M.G., Paolino D., Bulotta S., Ventura C.A., Russo D., Fresta M. Improved in vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes. J. Nanosci. Nanotechnol. 2008, 8:2102-2113.
18. Celia C., Malara N., Terracciano R., Cosco D., Paolino D., Fresta M., Savino R. Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells. Nanomedicine: NBM 2008, 4:155-166.
19. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003, 42:419-436.
20. Fritze A., Hens F., Kimpfler A., Schubert R., Peschka-Süss R. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim. Biophys. Acta 2006, 1758:1633-1640.
21. Paolino D., Lucania G., Mardente D., Alhaique F., Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Control. Release 2005, 106:99-110.
22. Shaw T.J., Senterman M.K., Dawson K., Crane C.A., Vanderhyden B.C. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Ther. 2004, 10:1032-1042.
23. Mudhakir D., Akita H., Khalil I.A., Futaki S., Harashima H. Pharmacokinetic analysis of the tissue distribution of octaarginine modified liposomes in mice. Drug Metab. Pharmacokinet. 2005, 20:275-281.
24. Gabizon A., Price D.C., Huberty J., Bresalier R.S., Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res. 1990, 50:6371-6378.
25. Zhigaltsev I.V., Maurer N., Akhong Q.F., Leone R., Leng E., Wang J., Semple S.C., Cullis P.R. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J. Control. Release 2005, 104:103-111.
26. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51:691-743.
27. Nagayasu A., Uchiyama K., Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv. Drug Deliv. Rev. 1999, 40:75-87.
28. Heinemann V., Xu Y.Z., Chubb S., Sen A., Hertel L.W., Grindey G.B., Plunkett W. Cellular elimination of 2′, 2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res. 1992, 52:533-539.
29. Bouffard D.Y., Laliberté J., Momparler R.L. Kinetic studies on 2′, 2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem. Pharmacol. 1993, 45:1857-1861.
30. Matsuda A., Sasaki T. Antitumor activity of sugar-modified cytosine nucleosides. Cancer Sci. 2004, 95:105-111.
31. Kundra P., Burman K.D. Thyroid cancer signalling pathways and use of targeted therapy. Endocrinol. Metab. Clin. North Am. 2007, 36:839-853.
32. Riesco-Eizaguirre G. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocr. Rel. Cancer. 2007, 14:957-977.
33. Smallridge R.C., Marlow L.A., Copland J.A. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Rel. Cancer 2009, 16:17-44.
34. M.G. Calvagno, D. Cosco, C. Celia, D. Paolino, D. Russo, M. Fresta, Liposomal multidrug carriers encapsulating gemcitabine and paclitaxel for the treatment of multi-drug resistent tumors, "33rd CRS Annual Meeting & Exposition", 22-26 July (2006) Austria Wien Center.
35. D. Cosco, M.G. Calvagno, S. Schenone, M. Celano, C. Celia, M. Botta, D. Russo, M. Fresta, Cytotoxic effects of gemcitabine and tyrosine kinase inhibitor containing liposomes on human anaplastic thyroid carcinoma cells, "33rd CRS Annual Meeting & Exposition", 22-26 July (2006) Austria Wien Center.
36. Tardi P.G., Gallagher R.C., Johnstone S., Harasym N., Webb M., Bally M.B., Mayer L.D. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim. Biophys. Acta 2007, 1768:678-687.
37. Celano M., Schenone S., Cosco D., Navarra M., Puxeddu E., Racanicchi L., Brullo C., Varano E., Alcaro S., Ferretti E., Botta G., Filetti S., Fresta M., Botta M., Russo D. Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. Endocr. Rel. Cancer 2008, 15:499-510.